Skip to main content

Bolt Biotherapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 21, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 21, 2024

BOLT$6.43-1.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 21, 2024BOLT BIOTHERAPEUTICS, INC.
By:/s/ Randall C. Schatzman, Ph.D.
Randall C. Schatzman, Ph.D.Chief Executive Officer

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Randall C. Schatzman, Ph.D. and William P. Quinn, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Randall C. Schatzman, Ph.D.Randall C. Schatzman, Ph.D.Chief Executive Officer and Director(Principal Executive Officer)March 21, 2024
/s/ William P. QuinnWilliam P. QuinnChief Financial Officer(Principal Financial and Accounting Officer)March 21, 2024
/s/ Laura BernerLaura BernerDirectorMarch 21, 2024
/s/ Edgar G. Engleman, M.D.Edgar G. Engleman, M.DDirectorMarch 21, 2024
/s/ James I. Healy, M.DJames I. Healy, M.D.DirectorMarch 21, 2024
/s/ Kathleen LaPorteKathleen LaPorteDirectorMarch 21, 2024
/s/ Frank D. LeeFrank D. LeeDirectorMarch 21, 2024
/s/ Richard A. Miller, M.D.Richard A. Miller, M.D.DirectorMarch 21, 2024
/s/ Brian O’CallaghanBrian O’CallaghanDirectorMarch 21, 2024
/s/ Nicole Onetto, M.D.Nicole Onetto, M.D.DirectorMarch 21, 2024
/s/ Mahendra G. Shah, Ph.D.Mahendra G. Shah, Ph.D.DirectorMarch 21, 2024
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.